<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856540</url>
  </required_header>
  <id_info>
    <org_study_id>2021/0105</org_study_id>
    <secondary_id>2021-A00585-36</secondary_id>
    <nct_id>NCT04856540</nct_id>
  </id_info>
  <brief_title>Adult Outcomes of Children With CAPS</brief_title>
  <acronym>CAPS</acronym>
  <official_title>Clinical Characteristic and Quality of Life Assessment in Adulthood of Patients With Cryopyrin Associated Periodic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients included in this study were followed up in the Internal Medicine and Paediatrics&#xD;
      Departments of the Lille CHU, the Paediatric Rheumatology and Immunology Department of the&#xD;
      Necker Enfant Malade Hospital in Paris and the Paediatric Rheumatology Department and&#xD;
      Internal Medicine of the Bicêtre Hospital in Paris. All patients selected presented one of&#xD;
      the 3 CAPS clinical phenotypes (CINCA/NOMID, Muckle-Wells or Cold Urticaria). The mutation&#xD;
      and the determination of the variant had to be confirmed by genetic analysis.&#xD;
&#xD;
      Patient data were collected from their medical records, retrospectively. Data collected&#xD;
      concern childhood period from appearance of symptoms, adulthood period, in the last year and&#xD;
      patients' way of life and quality of life upon the assessment. In addition, we collected&#xD;
      demographic data related to the patients' lifestyle (intoxications, living arrangements,&#xD;
      level of education) and we conducted individual telephone interviews lasting 15 minutes to&#xD;
      complete a quality of life questionnaire including the SF36 questionnaire.&#xD;
&#xD;
      The study aimed to describe the clinical symptoms of patients in adulthood and to assess&#xD;
      quality of life. We also wanted to compare the clinical phenotypes of patients according to&#xD;
      their genetic variant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical characteristics of patients with CAPS in adulthood</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the quality of life of patients with CAPS in adulthood</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the clinical status between childhood and adulthood</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the clinical status of patients according to their genetic variant.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Cryopyrin Associated Periodic Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients follow-up in a CEREMAIA reference or competence center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of FCAS, Muckle-Wells or NOMID/CINCA;&#xD;
&#xD;
          -  age &lt; 16 years at the apparition of the first symptoms of the disease;&#xD;
&#xD;
          -  age ≥ 16 years old at inclusion&#xD;
&#xD;
          -  follow-up in a CEREMAIA reference or competence center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 16 years at inclusion;&#xD;
&#xD;
          -  non-consenting patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hachulla, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Hachulla, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>eric.hachulla@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hop Claude Huriez Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
    <investigator>
      <last_name>Eric Hachulla, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAPS Cryopyrin associated periodic syndromes</keyword>
  <keyword>MWS Muckle-Wells syndrome</keyword>
  <keyword>CINCA Chronic infantile neurological cutaneous and articular syndrome ;</keyword>
  <keyword>FCAS Familial cold auto-inflammatory syndrome</keyword>
  <keyword>Phenotype ; Quality of life</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

